Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells

Gregory E. Holt, Pirouz Daftarian

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers elec-trostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid’s gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.

Original languageEnglish (US)
Pages (from-to)1349-1360
Number of pages12
JournalImmunotherapy
Volume10
Issue number16
DOIs
StatePublished - 2018

Keywords

  • Cancer immunology
  • Cancer vaccines
  • DNA plasmid
  • Gene therapy
  • Immunotherapy
  • Molecular immunology
  • Nanoparticles
  • Non-small-cell lung cancer
  • Vaccine vectors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells'. Together they form a unique fingerprint.

Cite this